Health Economics›Non-small cell lung cancer nonsquamous›Perioperative therapy

Perioperative therapy

Non-small cell lung cancer nonsquamous · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin, Pemetrexed, Durvalumab N/A - protocol	—	R 277 964	28d	—	—	~12	~R 2 165 465 indirect	—
Cisplatin, Pemetrexed, Durvalumab N/A - protocol	—	R 277 068	28d	—	—	~12	~R 2 161 879 indirect	—
Cisplatin, Pemetrexed, Pembrolizumab Variant #01	—	R 95 653	21d	—	—	35	R 2 924 218 PFS proxy	1
Carboplatin, Pemetrexed, Nivolumab Variant #01 Partial	—	R 14 563	28d	—	—	~13	~R 58 251 indirect	—
Cisplatin, Pemetrexed, Nivolumab Variant #01 Partial	—	R 13 666	21d	—	—	13	R 54 665 PFS proxy	1
Carboplatin and Paclitaxel (CP) and Nivolumab Variant #01 Partial	—	R 2 645	21d	—	—	~13	~R 10 579 PFS proxy · indirect	3

6 of 6 regimens shown